STOCK TITAN

Walgreens Boots Alliance (WBA) Stock Price, News & Analysis

WBA

Walgreens Boots Alliance (WBA) last traded on August 27, 2025. A Form 15-12G filed on September 8, 2025 ends the SEC registration of its shares.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
18 251 sessions, August 27, 2024 to August 27, 2025
Largest daily move
+27.5% close of January 10, 2025
1-year change
+26.8% closing prices, August 27, 2024 to August 27, 2025
1-month change
+3.2% closing prices, July 25, 2025 to August 27, 2025

Company Description

Written before these shares stopped trading.

Walgreens Boots Alliance, Inc. (historically trading under the symbol WBA) was an integrated healthcare, pharmacy and retail company in the pharmacies and drug stores industry within the retail trade sector. The group was formed through the combination of Walgreens and Alliance Boots in December 2014, bringing together businesses with long-standing community pharmacy and pharmaceutical wholesaling operations. According to prior company information, Walgreens Boots Alliance described itself as the first global pharmacy-led, health and wellbeing enterprise, with a heritage of trusted health care services dating back more than a century.

As a corporate group, Walgreens Boots Alliance included Walgreens in the United States, The Boots Group, and other healthcare-related businesses. Walgreens Boots Alliance also referenced one of the largest global pharmaceutical wholesale and distribution networks, serving pharmacies, doctors and other healthcare providers. Within this structure, community pharmacy locations and wholesale activities were central to how the organization participated in the healthcare and retail pharmacy markets.

In the United States and Puerto Rico, Walgreens has been a flagship brand within the Walgreens Boots Alliance family. Company disclosures state that Walgreens was founded in 1901 and serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, supported by leading omni-channel platforms. Walgreens has described itself as aiming to be the first choice for retail pharmacy and health services, emphasizing trusted relationships that support healthier futures for customers, patients, team members and communities.

Walgreens reports approximately 220,000 team members, including nearly 90,000 healthcare service providers, reflecting a large workforce focused on pharmacy and health services, as well as retail operations. Walgreens retail locations are described as a critical point of access and convenience in thousands of communities, with pharmacists playing an expanded role as part of the healthcare system and patients’ care teams. This role includes vaccinations, preventive services and pharmacy care delivered through community-based locations.

Within Walgreens Boots Alliance, specialty pharmacy has been an important area. Walgreens Specialty Pharmacy has expanded its limited distribution drug (LDD) network to include 265 products, and the company notes that this places it among the leading networks in specialty pharmacies. Limited distribution drugs are specialty medications available through select specialty pharmacies chosen by manufacturers, often involving complex regimens, high costs or special handling requirements. Walgreens Specialty Pharmacy operates as an independent specialty pharmacy not directly affiliated with a pharmacy benefit manager, which the company states allows it to collaborate with a broad range of partners.

Walgreens Specialty Pharmacy describes its focus on patients with rare, complex and chronic diseases, such as cancer, cystic fibrosis and Crohn’s disease, who often require additional support from their healthcare providers. The specialty pharmacy organization notes that it holds several national pharmacy accreditations and that its services are offered to nearly 300 million covered lives across the country. Walgreens Specialty Pharmacy highlights teams of specialty pharmacists, nurses, patient advocates, insurance specialists and other experts trained to support patients using specialty medications, including those that require unique storage, temperature control, handling, infusion or injection, and close clinical monitoring.

In addition to specialty medications, Walgreens has highlighted its role in vaccinations and preventive care. Company communications describe Walgreens pharmacies as a trusted destination for vaccinations and other preventive services, including flu shots for individuals three years and older at stores nationwide. Walgreens has emphasized convenient access through walk-ins, online scheduling, its mobile app and phone-based scheduling, as well as digital check-in features and the ability to coordinate multiple vaccines and family appointments in a single visit.

From a capital markets perspective, Walgreens Boots Alliance, Inc. previously had its common stock and certain notes listed on The Nasdaq Stock Market LLC under the symbols WBA, WBA25 and WBA26. On August 28, 2025, pursuant to an Agreement and Plan of Merger, Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., with the company surviving the merger as a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of investment funds managed by Sycamore Partners Management, L.P. An accompanying Form 8-K states that each share of company common stock was converted into the right to receive cash consideration and a divested asset proceed right, and that the company would cease to be a publicly traded company.

In connection with the completion of this merger, Walgreens Boots Alliance notified Nasdaq that its common stock and certain listed notes would be removed from listing, and Nasdaq filed a Form 25 on August 28, 2025 to strike these securities from listing and registration. A subsequent Form 15 filed on September 8, 2025 certified the termination of registration of the company’s common stock and specified notes under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of the duty to file reports under Sections 13 and 15(d). As a result, WBA common stock ceased trading on Nasdaq, and Walgreens Boots Alliance, Inc. transitioned to private ownership as a subsidiary of Blazing Star Parent, LLC.

Following the transaction, Sycamore Partners announced that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD would operate as separate standalone companies under private ownership. In a related announcement, Walgreen Co. stated that it is operating as a private standalone company following its acquisition by Sycamore Partners, in partnership with Stefano Pessina and his family. According to that announcement, Walgreens continues to describe itself as America’s leading independent retail pharmacy, with a renewed focus on its core pharmacy and retail platform, its stores and the customer experience.

Business focus and operations

Based on the company’s own descriptions, Walgreens Boots Alliance’s business historically centered on pharmacy-led health and wellbeing retail, community pharmacy services and pharmaceutical wholesale and distribution. Walgreens stores in the U.S. and Puerto Rico provide pharmacy services and retail offerings, while Walgreens Specialty Pharmacy focuses on specialty medications and support services for patients with complex conditions. The group has also highlighted its presence in multiple countries and its role in serving millions of customers and patients daily through both physical locations and digital platforms.

Specialty pharmacy operations emphasize support for medications that require special handling, storage and administration, as well as assistance with adherence and affordability for high-cost therapies. Walgreens Specialty Pharmacy notes that its independence from pharmacy benefit managers allows it to collaborate with payers, pharmaceutical companies, providers and other care partners, with the goal of helping manufacturers get medications to patients who need them.

Corporate status and trading history

Historically, Walgreens Boots Alliance, Inc. common stock traded on Nasdaq under the symbol WBA, and the company filed periodic reports with the U.S. Securities and Exchange Commission. Following shareholder approval of the merger agreement at a special meeting on July 11, 2025, and the completion of the merger on August 28, 2025, the company became a wholly owned subsidiary of Blazing Star Parent, LLC. The Form 8-K filed on August 28, 2025 and the Form 25 filed the same day document the cessation of trading and the removal of the securities from listing on Nasdaq. The Form 15 filed on September 8, 2025 documents the termination of registration and suspension of reporting obligations.

Role within the healthcare and retail pharmacy sector

Within the pharmacies and drug stores industry, Walgreens Boots Alliance and its Walgreens brand have described a role that combines community-based pharmacy services, specialty pharmacy capabilities and retail offerings. Walgreens retail locations are characterized as important access points for vaccinations, testing, treatment and pharmacy care, while Walgreens Specialty Pharmacy focuses on limited distribution drugs and patients with rare, complex and chronic conditions. Through these activities, the organization participates in broader healthcare delivery and medication management for large numbers of customers and patients.

Stock Performance

$11.98
No recent trading
Last close: August 27, 2025
+26.8%
1 year to August 27, 2025

Walgreens Boots Alliance (WBA) closed at $11.98 on August 27, 2025. In the 12 months to August 27, 2025, the price gained 26.8%.

See what a $1,000 investment in WBA would be worth today

Average down calculator for WBA

WBA Metrics & Rankings

Price returns through August 27, 2025. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Walgreens Boots Alliance has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 1 with negative movement. Key topics include acquisition, clinical trial. View all WBA news →

SEC Filings

Walgreens Boots Alliance has filed 10 recent SEC filings, including 4 Form S-8 POS, 3 Form 4, 1 Form 15-12G, 1 Form SCHEDULE 13G. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all WBA SEC filings →

Financial Highlights

Walgreens Boots Alliance generated $147.7B in revenue in FY2024, retaining a 18.0% gross margin, operating income reached -$14.1B (-9.5% operating margin), and net income was -$8.6B, reflecting a -5.9% net profit margin. Diluted earnings per share stood at -$10.01. The company generated $1.0B in operating cash flow. The current ratio was 0.68, measuring current assets divided by current liabilities.

$147.7B
Revenue (FY2024)
-$8.6B
Net Income (FY2024)
$1.0B
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for WBA.

WBA Company Profile & Sector Positioning

Walgreens Boots Alliance (WBA) operates in the Pharmaceutical Retailers industry within the broader Healthcare sector.

Investors comparing WBA often look at related companies in the same sector, including High Tide Inc. (HITI), PetMed Express, Inc. (PETS), Scienture Holdings, Inc. (SCNX), Ridgetech, Inc. (RDGT), and Pomdoctor Limited (POM). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate WBA's relative position within its industry.

Frequently Asked Questions

Walgreens Boots Alliance (WBA) last traded on August 27, 2025. A Form 15-12G filed on September 8, 2025 ends the SEC registration of its shares.

Walgreens Boots Alliance (WBA) has no recent trading. Its last close was $11.98 on August 27, 2025.

The FY2024 revenue of Walgreens Boots Alliance (WBA) is $147.7B, from its most recent completed fiscal year.

The FY2024 net income of Walgreens Boots Alliance (WBA) is -$8.6B, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Walgreens Boots Alliance (WBA) is -$10.01 for FY2024, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Walgreens Boots Alliance (WBA) is $1.0B for FY2024, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Walgreens Boots Alliance (WBA) is -5.9% for FY2024, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Walgreens Boots Alliance (WBA) is -9.5% for FY2024, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Walgreens Boots Alliance (WBA) is 18.0% for FY2024, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Walgreens Boots Alliance (WBA), current assets divided by current liabilities, was 0.68 at the end of FY2024, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Walgreens Boots Alliance (WBA) is $26.5B for FY2024, its most recent completed fiscal year.

The operating income of Walgreens Boots Alliance (WBA) is -$14.1B for FY2024, its most recent completed fiscal year. Learn about operating income.